EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review

Michel Sabé, Paul Grof, Nathan B Sackett, Sara Tai, Pamela Kryskow, Anya Bershad, Douglas Turkington, Matteo Buonarroti, Marco De Pieri, Pantelis Baniotopoulos, Mickael Eskinazi, Kerem Böge und 15 weitere

Schizophrenia Research · 2026-06 · 292 · 69-78

DOI: 10.1016/j.schres.2026.03.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Schizophrenia Research, 2026-06. Verfasst von Michel Sabé und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Addiction Psychiatry, Department of Psychiatry, University Hospitals of Geneva, 70, Grand-Pré, CH-1202, Geneva, Switzerland; Faculty of M…. Hauptthemen laut MEDLINE: Hallucinogens, Schizophrenia, Depression, Major Depressive Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensSchizophreniaDepressionMajor Depressive DisorderHumansAnimals

Stichwörter der Autor:innen

Depressive symptomsLSDMDMANegative symptomsPsilocybinPsychosis

Substanzen

Hallucinogens

Autor:innen und Institutionen

  • Division of Addiction Psychiatry, Department of Psychiatry, University Hospitals of Geneva, 70, Grand-Pré, CH-1202, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland; Division of Adult…
  • Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; Center for Novel Therapeutics in Addiction Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Washin…
  • Department of Clinical Psychology, School of Health Sciences, The University of Manchester, Manchester, UK.
  • Psychedelic-Assisted Therapy Post-Graduate Program, Health Sciences and Human Services, Vancouver Island University, Nanaimo, BC, Canada.
  • Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA, USA; VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

Förderung

  • NIH HHS

Zitieren

APA

Sabé, M., Grof, P., Sackett, N. B., Tai, S., Kryskow, P., Bershad, A., Turkington, D., Buonarroti, M., De Pieri, M., Baniotopoulos, P., Eskinazi, M., Böge, K., Leucht, S., Seragnoli, F., Furtado, L., Brakha, T. A., Curtis, L., Kirschner, M., Kaiser, S., …, & La Torre, J. (2026). Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review. Schizophrenia Research, 292, 69-78. https://doi.org/10.1016/j.schres.2026.03.003

Vancouver

Sabé M, Grof P, Sackett NB, Tai S, Kryskow P, Bershad A, et al. Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review. Schizophrenia Research. 2026;292:69-78. doi:10.1016/j.schres.2026.03.003

BibTeX
@article{Sab2026,
  author = {Sabé, Michel and Grof, Paul and Sackett, Nathan B and Tai, Sara and Kryskow, Pamela and Bershad, Anya and Turkington, Douglas and Buonarroti, Matteo and De Pieri, Marco and Baniotopoulos, Pantelis and Eskinazi, Mickael and Böge, Kerem and Leucht, Stefan and Seragnoli, Federico and Furtado, Léonice and Brakha, Tatiana Aboulafia and Curtis, Logos and Kirschner, Matthias and Kaiser, Stefan and Penzenstadler, Louise and Zullino, Daniele and Højlund, Mikkel and Gallo, Jade and Solmi, Marco and Sapienza, Jacopo and Bosia, Marta and La Torre, Joseph},
  title = {Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review},
  journal = {Schizophrenia Research},
  year = {2026},
  volume = {292},
  pages = {69--78},
  doi = {10.1016/j.schres.2026.03.003}
}
Kostenlos starten →